Publications by authors named "Tara Masterson"

Claim this Profile
T
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study.
Shigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, Kosei Matsue, Kazunori Imada, Tara J Masterson

Int J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1.
Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk, Brea Lipe, Noa Lavi, Tara Masterson

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results.
Jue Gong, Jie Zhou, Dongfen Yuan, Xuewen Ma, Deeksha Vishwamitra, Tara J Masterson

Clin Pharmacol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.
Niels W C J van de Donk, Ajai Chari, Thomas Martin, Amrita Krishnan, Leo Rasche, Tara Masterson

Cancer Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study.
Gang An, Jie Jin, Zhen Cai, Hongmei Jing, Chengcheng Fu, Tara J Masterson

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study.
Carolina Schinke, Cyrille Touzeau, Albert Oriol, María-Victoria Mateos, Don Stevens, Tara Masterson

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.
Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique C Minnema, Jesus G Berdeja, Tara Masterson

Lancet Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model.
Marie-Emilie Willemin, Jue Gong, Brandi W Hilder, Tara Masterson, Jaszianne Tolbert

Target Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
Ajai Chari, Amrita Krishnan, Leo Rasche, Jing Christine Ye, Alfred Garfall, Tara Masterson

Clin Lymphoma Myeloma Leuk· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.
Ola Landgren, Thomas J Prior, Tara Masterson, Christoph Heuck, Orlando F Bueno

Blood· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Paula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Tara Masterson

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Paula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Tara Masterson

Blood Cancer J· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, Niels W C J van de Donk, Jonathan L Kaufman, Tara Masterson

Haematologica· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
Mary Slavcev, Allison Spinelli, Elisabeth Absalon, Tara Masterson, Christoph Heuck

Clinicoecon Outcomes Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Ajai Chari, Paula Rodriguez-Otero, Helen McCarthy, Kenshi Suzuki, Vania Hungria, Tara Masterson

Br J Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Saad Z Usmani, Maria-Victoria Mateos, Vania Hungria, Shinsuke Iida, Nizar J Bahlis, Tara Masterson

J Cancer Res Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Tara Masterson

Lancet Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Saad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W C J van de Donk, Ajai Chari, Tara Masterson

Blood· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Jan de Jong, Peter Hellemans, Severijn De Wilde, Daniel Patricia, Tara Masterson

Leuk Lymphoma· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
Mark C Genovese, Elizabeth Hsia, Stanley M Belkowski, Caly Chien, Tara Masterson

J Rheumatol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.
Yanli Zhuang, Sally Lyn, Yuan Lv, Zhenhua Xu, Esther Bouman-Thio, Tara Masterson

Clin Drug Investig· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis